Cell Therapy Treatments in Development

• ALS

Ongoing Phase I safety clinical trial at Emory University advances to transplanting Neuralstem cells in the cervical region of the spinal cord, with first patient in cervical cohorts treated in November 2011. More

• Brain Cancer

Preclinical phase in collaboration with Loma Linda University as part of a U.S. Department of Defense-funded research program, entitled “Research to Treat Cancerous Brain Tumors with Neural Stem Cells.”

• Chronic Spinal Cord Injury

IND filed in U.S. In India, the company is evaluating potential trial surgery centers and collaborators for a planned IND filing expected in 2012. cSCI program in clinical protocol design stage at the Czech Institute of Experimental Medicine in Prague. More

• Chronic Stroke

Advanced preclinical program at University of Pittsburgh. In China, Phase I / II / III trials for chronic motor disorders from stroke expected to be underway in second half of 2012 in collaboration with BaYi Brain Hospital in Beijing. More

• Ischemic Spastic Paraplegia

Preclinical phase with the University of California at San Diego. Lead collaborator, Dr. Martin Marsala, PhD authored a peer-reviewed paper on study results. More

Drug Treatments in Development

• Alzheimer’s Disease

Preclinical phase with NSI-189, which was originally developed to address cognitive indications. Further clinical development on Alzheimer’s disease application pending NSI-189 major depressive disorder ongoing trial.

• Anxiety

Preclinical phase with NSI-189. Further clinical development on anxiety application pending NSI-189 major depressive disorder ongoing trial.

• Bipolar Disorder

Preclinical phase with NSI-189. Further clinical development on bipolar disorder application pending
NSI-189 major depressive disorder ongoing trial.

• Major Depressive Disorder
  

Ongoing Phase I trial for neuroregenerative small molecule drug, NSI-189, gained FDA approval in December 2011 to advance to Phase Ib. Scheduled to commence in March 2012, Phase Ib will test the safety and tolerability of escalating doses of NSI-189 for 28 daily administrations in 24 depressed patients, and is expected to take approximately six months to complete. More

• Schizophrenia

Preclinical phase with NSI-189. Further clinical development on schizophrenia application pending
NSI-189 major depressive disorder ongoing trial.